Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 2/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094793 | 0.79 | TRPA1 (0.37) | ALPLALOX15LMNAHPGDSMN1; SMN2 | |
| SCHEMBL19664706 | 0.78 | GABBR2 (0.41) | GABBR2GABBR1FFAR1CYP2C19ALPL | |
| 3,3-Diphenylpropanoic Acid SCHEMBL5283373 | 0.78 | GABBR2 (0.59) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL66473 | 0.78 | GABBR2 (0.59) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL5740483 | 0.76 | GABBR2 (0.57) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL28079188 | 0.76 | GABBR2 (0.57) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL28079326 | 0.76 | GABBR2 (0.57) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| 3,3-Diphenylpropanoic Acid SCHEMBL9100138 | 0.76 | GABBR2 (0.57) | GABBR2GABBR1FFAR1CYP2C19MAPT | |
| SCHEMBL170301 | 0.76 | SLC6A2 (0.55) | GABBR2GABBR1FFAR1CYP2C19HMOX2 | |
| SCHEMBL3371473 | 0.75 | GABBR2 (0.45) | GABBR2GABBR1FFAR1CYP2C19ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009522265-A | — | — | 2009-06-11 | — | — | JP | claimed |
| EP-1984344-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2533778-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011100285-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TERSERA THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | GABBR2 713/4885GABBR1 582/4885FFAR1 1811/4885 |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TPH1, TPH2, PTGIS | GABBR2 676/4885GABBR1 537/4885FFAR1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.